News
11-07-2023, 09:29 AM
The University of Texas MD Anderson Cancer Center and Jazz Pharmaceuticals plc today announced a five-year strategic research collaboration agreement to evaluate zanidatamab, Jazz's investigational HER2-targeted bispecific antibody, in multiple HER2-expressing cancers.
More... (https://www.news-medical.net/news/20231107/MD-Anderson-and-Jazz-Pharmaceuticals-collaborate-to-investigate-the-potential-of-zanidatamab-in-HER2-expressing-cancers.aspx)
More... (https://www.news-medical.net/news/20231107/MD-Anderson-and-Jazz-Pharmaceuticals-collaborate-to-investigate-the-potential-of-zanidatamab-in-HER2-expressing-cancers.aspx)